Abstract
Purpose
Data from solid tumor malignancies suggest that actual body weight (ABW) dosing improves overall outcomes. There is the potential to compromise efficacy when chemotherapy dosages are reduced, but the impact of dose adjustment on clinical response and toxicity in hematologic malignancies is unknown. The purpose of this study was to evaluate the outcomes of utilizing a percent of ABW for acute myeloid leukemia (AML) induction chemotherapy dosing.
Methods
This retrospective, single-center study included 146 patients who received 7 + 3 induction (cytarabine and anthracycline) for treatment of AML. Study design evaluated the relationship between percentage of ABW dosing and complete response (CR) rates in patients newly diagnosed with AML.
Results
Percentage of ABW dosing did not influence CR rates in patients undergoing induction chemotherapy for AML (p = 0.83); nor did it influence rate of death at 30 days or relapse at 6 months (p = 0.94). When comparing patients dosed at 90–100 % of ABW compared to <90 % ABW, CR rates were not significantly different in patients classified as poor risk (p = 0.907). All favorable risk category patients obtained CR.
Conclusions
Preemptive dose reductions for obesity did not influence CR rates for patients with AML undergoing induction chemotherapy and did not influence the composite endpoint of death at 30 days or disease relapse at 6 months.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Meyerhardt JA, Tepper JE, Niedzwiecki D et al (2004) Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol 22:648–657
Colleoni M, Li S, Gelber RD et al (2005) Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 366:1108–1110
Rosner GL, Hargis JB, Hollis DR et al (1996) Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 14:3000–3008
Griggs JJ, Manqu PB, Anderson H et al (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 30(99):1–10
Burhani M, Dave MJ, Venugopal P et al (2013) Influence of BMI on outcomes of high-dose cytarabine and mitoxantrone induction therapy for AML. [Abstract] J Clin Oncol 31 (Suppl; abstr 7106)
Wenzell CM, Gallagher EM, Earl M et al (2013) Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am J Hematol 88:906–909
National Comprehensive Cancer Network (NCCN) (2013) NCCN Clinical Practice Guidelines in Oncology. Acute myeloid leukemia. Version 2.2013. National Comprehensive Cancer Network
BMI Classification (2014) https://apps.who.int/bmi. World Health Organization. Accessed February 2014
Fernandez HF, Sun Z, Yao X et al (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361(13):1249–1259
Lin A, Othus M, McQuary A et al (2013) Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma 54(3):541–546
Acknowledgments
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award No. K23CA158146.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Bray, W.M., Bivona, C., Rockey, M. et al. Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight. Cancer Chemother Pharmacol 76, 691–697 (2015). https://doi.org/10.1007/s00280-015-2829-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-015-2829-1